Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration.
Pharmacokinetics of GVS-111, a new acylprolyldipeptide with nootropic properties and its penetration across the blood-brain barrier were studied in rats using HPLC. It was found that the dipeptide is absorbed in the gastrointestinal tract, enters the circulation, and penetrates through the blood-brain barrier in an unmodified state.
Boiko
S S
SS
Laboratory of Pharmacokinetics, Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow.
Ostrovskaya
R U
RU
Zherdev
V P
VP
Korotkov
S A
SA
Gudasheva
T A
TA
Voronina
T A
TA
Seredenin
S B
SB
D000284:Administration, Oral; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D004151:Dipeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D018697:Nootropic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats
D004151:Dipeptides; D018697:Nootropic Agents; C103871:ethyl phenylacetyl-Pro-Gly